Serum HBV RNA is a Potential Predictor of Hepatitis B Surface Antigen Reversion-Reference-Cited by-同舟云学术

Serum HBV RNA is a Potential Predictor of Hepatitis B Surface Antigen Reversion

Published:2018-09-24 Issue:10 Volume:2 Page:1168-1171
ISSN:2471-254X
Container-title:Hepatology Communications
language:en
Short-container-title:Hepatology Communications

Author:

Wang Jie¹,Chen Xiangmei¹,Wu Yali²,Cao Zhenhuan²,Wang Leijie¹,Huang Hongxin¹,Chen Xinyue²,Lu Fengmin¹

Affiliation:

1. State Key Laboratory of Natural and Biomimetic Drugs, Department of Microbiology and Infectious Disease Center, School of Basic Medical Sciences Peking University Health Science Center Beijing China

2. International Medical Department Beijing Youan Hospital, Capital Medical University Beijing China

Funder

National Natural Science Foundation of China

Natural Science Foundation of Beijing Municipality

Publisher

Wiley

Subject

General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/hep4.1249

Reference7 articles.

1. Hepatitis B cure: From discovery to regulatory approval

2. HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability

3. Serum hepatitis B virus RNA is encapsidated pregenome RNA that may be associated with persistence of viral infection and rebound

4. Potent hepatitis B surface antigen response to treatment of hepatitis-B-e-antigen-positive chronic hepatitis B with α-interferon plus a nucleos(t)ide analog

5. Durability of hepatitis B surface antigen seroclearance in untreated and nucleos(t)ide analogue‐treated patients;Yip TC;J Hepatol,2017

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Detection technology and clinical applications of serum viral products of hepatitis B virus infection;Frontiers in Cellular and Infection Microbiology;2024-07-05

2. Editorial:HBsAgseroclearance after pegylated interferon treatment—The beginning of the end. Authors' reply;Alimentary Pharmacology & Therapeutics;2023-10-26

3. Nucleos(t)ide analogues altered quasispecies composition of hepatitis B virus (HBV)‐resistant mutations in serum HBV DNA and serum HBV RNA;Journal of Medical Virology;2023-03

4. Serum HBV RNA is associated with liver fibrosis regression in HBeAg ‐positive chronic hepatitis B patients treated with nucleos(t)ide analogues;Journal of Viral Hepatitis;2023-01-10

5. The potential effect of HBV vaccination on off-treatment HBsAg reversion after interferon-induced HBsAg clearance;Human Vaccines & Immunotherapeutics;2023-01-02